Loading...

PHAT PHATHOM PHARMACEUTICALS INC US FDA Inspections 8-K Filing

PHTH

PHT

PHATHOM PHARMACEUTICALS INC

(PHAT)

2025 8-K

Show Summary

Show Summary

Other Special Situation

Pre-Market Approval

Financial Statements

Director Appointment

Financial Results

Earnings Report

Financial Results

Financial Results Announcement

Financial Results Announcement

Financial Results Announcement

Other Special Situation

Bylaws Amendment

Loan Agreement Amendment

FDA Acceptance of New Drug ...

Financial Results Announcement

FDA Approval for VOQUEZNA T...

FDA Stability Data Submission

Financial Results Announcement

Stock Option Exchange

Stock Option Exchange

FDA Acknowledges NDA Resubm...

Annual Meeting and Changes ...

Underwriting Agreement

Resubmission of New Drug Ap...

Financial Results Announcement

Regulatory Update

Financial Results Announcement

Positive Study Results for ...

External Links:

On June 16, 2025, Phathom Pharmaceuticals confirmed that its drug VOQUEZNA is granted a full 10-year non-patent exclusivity period until May 3, 2032, enhancing its market position.

AI Assistant

PHATHOM PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.